Is Argenx Stock a Buy Now?
Biotech company Argenx (NASDAQ: ARGX) is on a roll. Shares of the company recently soared by almost 30% in just one day. It owes these gains to great news from the clinic that could lead to a key approval down the road. That all sounds good, but while short-term gains are nice, investors with a much longer horizon should take the time to look at the totality of the business before deciding to press the buy button.
Let's look closer at Argenx and figure out whether buying its shares is worth it after the recent rally.
Argenx focuses on developing therapies in the field of immunology. The company currently has just one product on the market, Vyvgart, which treats generalized myasthenia gravis (gMG). This is a rare, chronic, and potentially life-threatening disease that produces muscle weakness. On June 20, Argenx announced that the U.S. Food and Drug Administration (FDA) had approved Vyvgart Hytrulo -- the subcutaneous version of Vyvgart -- in treating gMG.
Source Fool.com
